首页> 外文期刊>Acta oncologica. >Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy
【24h】

Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy

机译:图像引导体积调制弧放疗和MR引导日常自适应放疗前列腺癌立体定向体放射治疗的日常剂量变化

获取原文
获取原文并翻译 | 示例
           

摘要

Aim To evaluate differences between MR-guided daily-adaptive RT (MRgRT) and image-guided RT (IGRT) with or without fiducial markers in prostate cancer (PCa) stereotactic body radiotherapy (SBRT) in terms of dose distribution on critical structures. Material and methods Two hundred treatment sessions in 40 patients affected by low and intermediate PCa were evaluated. The prescribed dose was 35 Gy in 5 fractions delivered on alternate days. MRgRT patients (10) were daily recontoured, re-planned, and treated with IMRT technique. IGRT patients without (20) and with (10) fiducials were matched on soft tissues or fiducials and treated with VMAT technique. Respective CBCTs were retrospectively delineated and the prescribed plan was overlaid for dosimetric analysis. The daily dose for rectum, bladder, and prostate was registered. Results MRgRT resulted in a significantly lower rate of constraints violation as compared to IGRT without fiducials, especially for rectum V28Gy, rectum V32Gy, rectum V35Gy, rectum Dmax, and bladder Dmax. IGRT with fiducials reported high accuracy levels, comparable to MRgRT. MRgRT and IGRT with fiducials reported no significant prostate CTV underdosage, while IGRT without fiducials was associated with occasional cases of prostate CTV under dosage. Conclusion MR-guided daily-adaptive SBRT seems a feasible and accurate strategy for treating prostate cancer with ablative doses. IGRT with the use of fiducials provides a comparable level of accuracy and acceptable real-dose distribution over treatment fractions. Future study will provide additional data regarding the tolerability and the clinical outcome of this new technological approach.
机译:None

著录项

  • 来源
    《Acta oncologica.》 |2021年第2期|共7页
  • 作者单位

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

    IRCCS Sacro Cuore Don Calabria Hosp Canc Care Ctr Adv Radiat Oncol Dept Negrar Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号